SCHEMBL21260652

SCHEMBL21260652

COc1ccc(C(=O)Nc2sc3c(c2C(=O)O)CCC(C(C)(C)C)C3)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
ANO1 Q5XXA6 3/20 0.60
THRB P10828 2/20 0.59
KMT2A Q03164 5/20 0.54
PDE4B Q07343 2/20 0.54
PDE4D Q08499 1/20 0.54
POLB P06746 1/20 0.51
TNF P01375 2/20 0.51
NOD1 Q9Y239 2/20 0.51
MEN1 O00255 3/20 0.51
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TP53 P04637 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
GLO1 Q04760 1/20 0.50
NOD2 Q9HC29 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247250 0.87 THRB (0.68) MAPTANO1THRBKMT2APDE4B
SCHEMBL22696763 0.85 MAPT (0.51) MAPTANO1THRBKMT2APDE4B
SCHEMBL21260759 0.83 MAPT (0.71) MAPTANO1THRBKMT2APDE4B
SCHEMBL21260681 0.82 MAPT (0.64) MAPTANO1THRBKMT2APDE4B
SCHEMBL21260684 0.81 THRB (0.86) MAPTANO1THRBKMT2APDE4B
SCHEMBL21247136 0.79 TNF (0.75) MAPTANO1THRBKMT2APDE4B
SCHEMBL21260653 0.79 MAPT (0.77) MAPTANO1THRBKMT2APDE4B
SCHEMBL22686814 0.79 MAPT (0.63) MAPTANO1THRBKMT2APDE4B
SCHEMBL918990 0.79 MAPT (0.77) MAPTANO1THRBKMT2APDE4B
SCHEMBL21247290 0.79 GLO1 (0.53) MAPTTHRBKMT2APDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US claimed
US-11603368-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-03-14 US disclosed
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154949-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH MAPT 2107/4885ANO1 4015/4885THRB 1218/4885
US-11603368-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH MAPT 2107/4885ANO1 4015/4885THRB 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.